Compared, cited

Enclomiphene vs TRT

Q: Is enclomiphene an alternative to TRT?

It is framed that way because it raises the body's own testosterone while preserving sperm production, whereas exogenous testosterone replaces the hormone and suppresses both LH/FSH and sperm. But enclomiphene is not FDA-approved - it is compounded and used off-label - and which approach fits is a prescriber's decision. This is educational information, not medical advice.

Q: Why does TRT lower sperm count but enclomiphene does not?

Exogenous testosterone signals the brain that levels are sufficient, so LH and FSH fall and the testicular signaling that drives sperm production shuts down. Enclomiphene instead blocks estrogen feedback at the hypothalamus, raising LH and FSH, so the testicles keep working and spermatogenesis is preserved.

Q: Is enclomiphene FDA-approved?

No. It was developed as Androxal and studied through Phase 3, but it was never approved. It is available only as a compounded, off-label drug.

Two ways to raise a man's testosterone that work in opposite directions. Enclomiphene turns the body's own signal up and preserves sperm production; exogenous testosterone replaces the hormone from outside and suppresses the axis that makes sperm. Here is the cited contrast.

Last updated August 2026

Pepteca is a cited peptide reference. We do not sell peptides and take no affiliate money. Every figure below traces to a source on the linked library pages, with a clear line between what is clinically studied and what is community-reported.

At a glance	Enclomiphene	Testosterone (TRT)
What it is	Oral SERM (trans-isomer of clomiphene)	Injected testosterone ester (exogenous hormone)
Effect on the HPG axis	Raises the body's own LH, FSH, and testosterone	Suppresses LH and FSH; supplies testosterone from outside
Effect on sperm	Preserves it (~176 M/mL vs <12 M/mL on testosterone at 3 mo)	Suppresses sperm production
FDA status	Not FDA-approved; compounded, off-label	FDA-approved for hypogonadism
Route	Oral, once daily (12.5-25 mg in trials)	Intramuscular or subcutaneous injection
Controlled status	Not a controlled substance	Schedule III

Opposite mechanisms

This is the core distinction. Enclomiphene is a SERM: it occupies estrogen receptors at the hypothalamus and blocks estrogen's negative-feedback signal, so the brain sends more luteinizing hormone and follicle-stimulating hormone to the testicles and they make more of the body's own testosterone. Exogenous testosterone does the reverse - it raises circulating testosterone directly, the axis reads that as sufficient, and LH and FSH fall. Because sperm production depends on that intratesticular signaling, the two approaches pull fertility in opposite directions.

The fertility contrast, cited

In the Repros comparison, men on enclomiphene held a mean sperm concentration around 176 million/mL while men on testosterone dropped below 12 million/mL after three months, because enclomiphene raises endogenous LH and FSH rather than replacing testosterone from outside (PMC5009465). A separate meta-analysis found SERM therapy produced sperm concentrations about 70 million/mL higher than testosterone gel, while total testosterone was comparable between the two (PMC12510335). On the other side, chronic exogenous testosterone is documented to inhibit the hypothalamic-pituitary-gonadal axis and impair sperm production, which is why hCG is sometimes added to a testosterone protocol to help preserve fertility (Fink 2024).

Status and route differ

Enclomiphene has no FDA-approved product: Repros Therapeutics developed it as Androxal through Phase 3 but it was never approved, so it exists only as a compounded, off-label oral drug (12.5 to 25 mg once daily in the trials). Testosterone is FDA-approved for hypogonadism, injected, and a Schedule III controlled substance. Enclomiphene also depends on a pituitary that can still respond, so it targets secondary (hypogonadotropic) hypogonadism; testosterone replaces the hormone regardless. Which route fits is a prescriber's decision.

Who fits which

Considerations around enclomiphene

Raised the body's own testosterone while preserving sperm production in trials, taken orally, and relevant to secondary hypogonadism where the pituitary can still respond. The catch is status: it is not FDA-approved and is only available compounded and off-label. Educational information, not a recommendation.

Considerations around testosterone / TRT

FDA-approved and replaces testosterone directly regardless of pituitary responsiveness, but it suppresses the axis and sperm production - hCG is sometimes added when fertility matters. It is a Schedule III controlled substance and a prescriber-managed therapy.

Why it is not purely either/or

Fertility is the usual dividing line: the fertility-preserving profile is what draws people to enclomiphene as an alternative, and adjuncts like hCG or a SERM are sometimes used around testosterone to protect fertility. These are reference considerations, not a protocol.

The cited card

Enclomiphene

SERM

The cited card

Testosterone (TRT)

testosterone ester

Questions people ask

Is enclomiphene an alternative to TRT?

It is framed that way because it raises the body's own testosterone while preserving sperm production, whereas exogenous testosterone replaces the hormone and suppresses both LH/FSH and sperm. But enclomiphene is not FDA-approved - it is compounded and used off-label - and which approach fits is a prescriber's decision. This is educational information, not medical advice.

Why does TRT lower sperm count but enclomiphene does not?